BioSpace News Archive

Inscopix, Inc. announced the official release of Inscopix’s new multimodal behavioral technology called the nVision System, at Neuroscience 2022 being held in San Diego, California, November 12-16.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvementsa of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with TREMFYA®.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November.

Gamida Cell Ltd. today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the Jefferies London Healthcare Conference, November 17, 2022 with a presentation at 9:10 a.m. GMT.

Sonoma Biotherapeutics, Inc. will be presenting key data at the American College of Rheumatology (ACR) Convergence 2022 Scientific Sessions highlighting preclinical data from the company’s autologous T reg therapy for the treatment of rheumatoid arthritis (RA).

Equillium, Inc. today announced that it has initiated a Phase 2 open-label study of EQ101 to assess efficacy and safety in adult subjects with moderate to severe alopecia areata.

Global molecular diagnostics innovator Sense Biodetection (Sense) today announced it has entered into a strategic agreement with Bio Nuclear Diagnostics, Inc. (BND) for the non-exclusive distribution in Canada of Sense’s Veros instrument-free, point-of-care molecular testing platform.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD) (OTCQB: SQIDF) today announced that it has entered into a funding agreement (the “Contribution Agreement”) with the Federal Economic Development Agency for Southern Ontario (“FedDev Ontario”) to support the Company’s manufacturing scale-up and commercialization of its pipeline of products in development, including the Company’s recently approved RALI-DX IL-6 test.

AbCellera (Nasdaq: ABCL) today announced the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.